20161005-ov-vancouver-vacv-antibody-poster-final-fr
Catégorie : dates
Engineering Oncolytic Vaccinia Virus with Improved Cancer Killing Abilities
Johann Foloppe, et al. 10th International Meeting on Replicating Oncolytic Virus Therapeutics, Vancouver, Canada – 1-4 October 2016 Download the poster here Poster Presentation Collaboration between Transgene – HTS facility IGBMC, Illkirch – France IREBS, Illkirch, France – ICube, Strasbourg, France
Point sur la stratégie de développement et information financière du 1er semestre 2016
20160905 – H1 update – FR – V10
Transgene annonce ses prochains rendez-vous avec les investisseurs
20160901 – Prochains rdv investisseurs – FR
Poursuite de l’étude de phase 1/1b de TG1050 de Transgene dans l’hépatite B chronique suite à la recommandation positive du Comité d’Évaluation de la Sécurité
20160721 – Safety TG1050 FR Vdef
Improvement of MVA-based Vaccines by Expression of an Autophagy Inhibitor
Anita Spindler, et al. XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016 Download the poster here Poster Presentation
Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death-1 (PD-1) allow their intratumoral delivery and an improved tumor growth inhibition
Jean Baptiste Marchand, et al. XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016 Download the poster here Poster Presentation
Evaluation of a novel oncolytic Raccoonpox virus expressing the bifunctional FCU1 suicide gene
Marine Ricordel, et al. XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016 Download the poster here Poster Presentation
Oncolytic vaccinia virus TG6002 demonstrates potent efficiency in pancreatic tumor alone and in combination with standard chemotherapies
Johann Foloppe, et al. XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016 Download the poster here Poster Presentation
A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy
Ghassan K. Abou-Alfa, et al. ASCO Annual Meeting 2016, June 3-7, 2016, Chicago Illinois Download the poster here Poster Presentation